Cascata Call – Extended partnership “Health Extended ALLiance for Innovative Therapies, Advanced Labresearch, and Integrated Approaches of Precision Medicine” – HEAL Italia Spoke N.5 – Next-Gen Therapeutics

October 9, 2024

FORM FACILITATION

Contribution/Repayable fund

REGIONS

Piedmont, Lombardy, Valle d'Aosta/Vallée d'Aoste, Liguria, Abruzzo, Molise, Basilicata, Calabria, Campania, Puglia, Sicily, Trentino-Alto Adige/Südtirol, Veneto, Sardinia, Tuscany, Friuli-Venezia Giulia, Emilia- Romagna, Umbria, Marche, Lazio

SECTOR

Health

ALLOWED EXPENSE

360000 €

INCENTIVE STATUS

CLOSED

OPENING DATE

CLOSING DATE

December 11, 2023
February 12, 2024

NOTES

No additional notes

Things

The overall objective of the project is to provide new, cost-effective and evidence-based predictive and non-invasive diagnostic pathways for faster, earlier, more precise, accessible and economical prediction, detection and monitoring of monogenic (rare) diseases, polygenic (cardiovascular and metabolic) and cancer, as well as to identify innovative and effective therapeutic approaches. The HEAL ITALIA project also aims to identify and reduce inequalities (extremely large between Northern and Southern Italy) by developing an interregional collaboration roadmap to define evidence-based pathways that can be easily used in clinical practice. 

Who is it aimed at?

The HEAL Italia Program promotes a scheme based on cascade funding to support Proof-of-Concept (PoC) projects with industrial research and experimental development processes involving companies (SMEs, start-ups, spin-offs1 ), IRCCS, research organisations, foundations and other entities interested in the creation/implementation of valorisation and acceleration programs activated by the Spokes and managed in collaboration with the HUB. 

What does it predict

The objective is to push the levels of technological maturity - TRL (Technology Readiness Levels) - envisaged by the Heal Italia Programme, through the involvement of subjects external to the Extended Partnership, strongly interested in introducing/implementing significant innovations that act as a trailblazer and/or as tool for accelerating and specializing the activities carried out by the Spokes for the search for technologically advanced solutions, in relation to products, processes and services transferable to the areas of intervention of Precision Medicine. The Call supports proposals referring to activities that require a level of technological maturity higher than a TRL of 3. Support, therefore, mainly refers to the development/implementation of technologies with extremely advanced content, including conceptual verification and prototypes for the validation of the technology , demonstration activities for pilot projects and feasibility studies also in order to be able to evaluate high potential activities and support the creation of spin-offs and start-ups. 

Objective – Purpose

Innovation and research

Form – Facilitation

Contribution/Repayable fund

Minimum Allowable Expenditure

360000 €

Maximum Allowable Expenditure

1425000 €

Allowed Costs

Buildings and land, Professional training, Personnel costs, Raw materials, consumables and goods, Services, patents and licenses, General expenses/other charges, Plant/Machinery/Equipment

Minimum concession that can be granted

360.000 €

Maximum grantable benefit

475000 €
Subject type
Public body, company, university/research body

Dimension

Micro-enterprise, Medium-sized enterprise, Large enterprise, Unclassifiable/classified, Small enterprise

Activity sector

Health

ATECO

All economic sectors eligible to receive aid

Regions

Piedmont, Lombardy, Valle d'Aosta/Vallée d'Aoste, Liguria, Abruzzo, Molise, Basilicata, Calabria, Campania, Puglia, Sicily, Trentino-Alto Adige/Südtirol, Veneto, Sardinia, Tuscany, Friuli-Venezia Giulia, Emilia- Romagna, Umbria, Marche, Lazio

Municipalities

--

Special territorial scope

SEZ

Other features

--

Managing entity

University of Milan - Bicocca

Primary regulatory basis

MUR Directorial Decree n. 341 of 15 March 2022, registered at the Court of Auditors on 03/31/2022 n. 748.
Secondary regulatory basis
--

Implementation measure

MUR Directorial Decree n. 341 of 15 March 2022, registered at the Court of Auditors on 03/31/2022 n. 748.

References Official Journal

--

Incentive allocation

1425000 €

Reference site

https://www.unimib.it/ricerca/opportunita/bandi-cascata-pnrr

Is this the right announcement for you?

Let's find out together, fill out the form and request a free consultation